I've been following the company for over three years, and this is the BEST PR I have seen this company execute. I recently bought back in earlier this week. It appears that David Sherris (formerly of OXGN) is networking with pharma to execute a few R&D collaborations for PPHM's VTA platform. I have a PDF copy of Thorpe's entire essay in the Cancer Journal I'd be happy to send you if you would like to read it. Apparently pharma is reviewing one of PPHM's VTAs for an ocular indication, it's unclear to me if it is the 2C3 candidate or the anti-PS (Vatuximab) candidate.
Market Data 
Markets 
AI
